{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:56:03Z","timestamp":1793404563761,"version":"4.5.0"},"reference-count":137,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coronary stents have revolutionized the treatment of coronary artery disease. Compared with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel closure but were limited by in-stent restenosis (ISR) due to smooth muscle cell proliferation and neointimal hyperplasia. The first-generation drug-eluting stent (DES), with its antiproliferative drug coating, offered substantial advantages over BMSs as it mitigated the risk of ISR. Nonetheless, they had several design limitations that increased the risk of late stent thrombosis. Significant advances in stent design, including thinner struts, enhanced polymers\u2019 formulation, and more potent antiproliferative agents, have led to the introduction of new-generation DES with a superior safety profile. Cardiologists have over 20 different DES types to choose from, each with its unique features and characteristics. This review highlights the evolution of stent design and summarizes the clinical data on the different stent types. We conclude by discussing the clinical implications of stent design in high-risk subsets of patients.<\/jats:p>","DOI":"10.1093\/cvr\/cvac105","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T16:46:48Z","timestamp":1657039608000},"page":"631-646","source":"Crossref","is-referenced-by-count":70,"title":["Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside"],"prefix":"10.1093","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3015-3361","authenticated-orcid":false,"given":"Johny","family":"Nicolas","sequence":"first","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Andrea","family":"Pivato","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"},{"name":"Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini, 4, 20090 Pieve Emanuele MI , Italy"},{"name":"IRCCS Humanitas Research Hospital , via Manzoni 56, 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-2658","authenticated-orcid":false,"given":"Mauro","family":"Chiarito","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"},{"name":"Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini, 4, 20090 Pieve Emanuele MI , Italy"},{"name":"IRCCS Humanitas Research Hospital , via Manzoni 56, 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-5055","authenticated-orcid":false,"given":"Frans","family":"Beerkens","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"},{"name":"Cardiovascular Department, Humanitas Gavazzeni , Via Mauro Gavazzeni, 21, 24125 Bergamo BG , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2023050214505130900_cvac105-B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fcvm.2014.00015","article-title":"Balloon angioplasty \u2013 the legacy of Andreas Gr\u00fcntzig, MD (1939\u20131985)","volume":"1","author":"Barton","year":"2014","journal-title":"Front Cardiovasc Med"},{"key":"2023050214505130900_cvac105-B2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"331","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease","volume":"331","author":"Fischman","year":"1994","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJM199101033240103","article-title":"Angiographic follow-up after placement of a self-expanding coronary-artery stent","volume":"324","author":"Serruys","year":"1991","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/01.CIR.83.1.148","article-title":"Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study","volume":"83","author":"Schatz","year":"1991","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1161\/01.CIR.86.6.1836","article-title":"Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience","volume":"86","author":"Ellis","year":"1992","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.294.10.1215","article-title":"Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial","volume":"294","author":"Stone","year":"2005","journal-title":"JAMA"},{"key":"2023050214505130900_cvac105-B8","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1001\/jama.299.24.2868","article-title":"Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents","volume":"299","author":"Malenka","year":"2008","journal-title":"JAMA"},{"key":"2023050214505130900_cvac105-B9","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.ahj.2009.03.016","article-title":"Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial","volume":"158","author":"Di Lorenzo","year":"2009","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B11","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1093\/eurheartj\/ehl282","article-title":"Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis","volume":"27","author":"Nordmann","year":"2006","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4244\/EIJV3I5A95","article-title":"Have we been misled by the ESC DES firestorm?","volume":"3","author":"Cook","year":"2008","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrcardio.2010.14","article-title":"New drug-eluting stent concepts","volume":"7","author":"Wessely","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2023050214505130900_cvac105-B14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cvr\/cvt115","article-title":"Biological responses in stented arteries","volume":"99","author":"Chaabane","year":"2013","journal-title":"Cardiovasc Res"},{"key":"2023050214505130900_cvac105-B15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1093\/eurheartj\/ehr182","article-title":"Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial","volume":"32","author":"Guti\u00e9rrez-Chico","year":"2011","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B16","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ahj.2011.09.005","article-title":"Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer","volume":"162","author":"Guti\u00e9rrez-Chico","year":"2011","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2013.04.001","article-title":"Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: in vivo assessment with optical coherence tomography","volume":"166","author":"Guti\u00e9rrez-Chico","year":"2013","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/jcp.2005.025742","article-title":"In stent restenosis: bane of the stent era","volume":"59","author":"Mitra","year":"2006","journal-title":"J Clin Pathol"},{"key":"2023050214505130900_cvac105-B19","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0735-1097(99)00486-6","article-title":"Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen","volume":"35","author":"Grewe","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jcin.2011.05.025","article-title":"Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis","volume":"4","author":"Inoue","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","article-title":"The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B23","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","article-title":"Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment","volume":"36","author":"Otsuka","year":"2015","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B25","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1161\/ATVBAHA.115.306251","article-title":"Neoatherosclerosis from a pathologist\u2019s point of view","volume":"35","author":"Romero","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023050214505130900_cvac105-B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4244\/EIJ-D-20-00539","article-title":"Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis","volume":"17","author":"Nakamura","year":"2021","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B27","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jacc.2017.02.050","article-title":"Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease","volume":"69","author":"Lemesle","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.058560","article-title":"Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study","volume":"125","author":"R\u00e4ber","year":"2012","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.amjcard.2016.10.038","article-title":"Impact of patient and lesion complexity on long-term outcomes following coronary revascularization with new-generation drug-eluting stents","volume":"119","author":"Koskinas","year":"2017","journal-title":"Am J Cardiol"},{"key":"2023050214505130900_cvac105-B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","article-title":"Predictors of stent thrombosis and their implications for clinical practice","volume":"16","author":"Gori","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2023050214505130900_cvac105-B31","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1253\/circj.CJ-10-1160","article-title":"Characteristics and predictors of drug-eluting stent thrombosis: results from the multicenter \u2018Korea Stent Thrombosis (KoST)\u2019 registry","volume":"75","author":"Park","year":"2011","journal-title":"Circ J"},{"key":"2023050214505130900_cvac105-B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0002-8703(92)90742-E","article-title":"Effects of design geometry of intravascular endoprostheses on stenosis rate in normal rabbits","volume":"123","author":"Tominaga","year":"1992","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0735-1097(92)90476-4","article-title":"Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model","volume":"19","author":"Schwartz","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/01.CIR.78.3.646","article-title":"Intra-arterial stenting in the atherosclerotic rabbit","volume":"78","author":"Robinson","year":"1988","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B35","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1161\/ATVBAHA.119.313246","article-title":"Variation in coronary atherosclerosis severity related to a distinct LDL (low-density lipoprotein) profile: findings from a familial hypercholesterolemia pig model","volume":"39","author":"Hoogendoorn","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023050214505130900_cvac105-B36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1148\/radiology.203.2.9114109","article-title":"Relationship between plaque mass and neointimal hyperplasia after stent placement in Yucatan micropigs","volume":"203","author":"de Smet","year":"1997","journal-title":"Radiology"},{"key":"2023050214505130900_cvac105-B37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/heart.89.2.133","article-title":"Drug eluting stents: are human and animal studies comparable?","volume":"89","author":"Virmani","year":"2003","journal-title":"Heart"},{"key":"2023050214505130900_cvac105-B38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1056\/NEJM199602293340903","article-title":"Three-year follow-up after implantation of metallic coronary-artery stents","volume":"334","author":"Kimura","year":"1996","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/01.CIR.103.1.14","article-title":"Radioactive stents delay but do not prevent in-stent neointimal hyperplasia","volume":"103","author":"Kay","year":"2001","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B40","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/S0735-1097(00)01020-2","article-title":"Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months","volume":"36","author":"Drachman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jcin.2011.11.002","article-title":"Stent longitudinal integrity bench insights into a clinical problem","volume":"4","author":"Ormiston","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B42","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4244\/EIJV9I12A243","article-title":"Longitudinal compression behaviour of coronary stents: a bench-top comparative study","volume":"9","author":"Barragan","year":"2014","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1161\/01.RES.76.3.412","article-title":"Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells","volume":"76","author":"Marx","year":"1995","journal-title":"Circ Res"},{"key":"2023050214505130900_cvac105-B44","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/01.CIR.96.2.636","article-title":"Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery","volume":"96","author":"Axel","year":"1997","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B45","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/01.CIR.98.3.224","article-title":"Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses","volume":"98","author":"Komatsu","year":"1998","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B46","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action.","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"2023050214505130900_cvac105-B47","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1161\/01.CIR.0000164271.01172.1A","article-title":"Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents","volume":"111","author":"Sousa","year":"2005","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B48","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/01.CIR.0000086926.62288.A6","article-title":"Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions","volume":"108","author":"Colombo","year":"2003","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jacc.2005.03.069","article-title":"The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES)","volume":"46","author":"Serruys","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B50","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B51","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.carrad.2004.04.002","article-title":"Thrombosis and drug-eluting stents: a critical appraisal","volume":"5","author":"Kereiakes","year":"2004","journal-title":"Rev Cardiovasc Med"},{"key":"2023050214505130900_cvac105-B53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.107.730010","article-title":"Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries","volume":"120","author":"Wilson","year":"2009","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B54","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","article-title":"Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B55","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jacc.2016.11.055","article-title":"10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents","volume":"69","author":"Gall\u00f8e","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B56","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0022-2836(68)80024-5","article-title":"Studies of the binding of actinomycin and related compounds to DNA","volume":"35","author":"M\u00fcller","year":"1968","journal-title":"J Mol Biol"},{"key":"2023050214505130900_cvac105-B57","first-page":"1363","article-title":"Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial","volume":"44","author":"Serruys","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B58","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jbm.a.31340","article-title":"Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation","volume":"83","author":"Hasebe","year":"2007","journal-title":"J Biomed Mater Res A"},{"key":"2023050214505130900_cvac105-B59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/joic.12303","article-title":"Stent coating integrity of durable and biodegradable coated drug eluting stents","volume":"29","author":"Yazdani","year":"2016","journal-title":"J Interv Cardiol"},{"key":"2023050214505130900_cvac105-B60","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","article-title":"A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial","volume":"57","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B61","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/17434440.2020.1736037","article-title":"Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy","volume":"17","author":"Blum","year":"2020","journal-title":"Expert Rev Med Devices"},{"key":"2023050214505130900_cvac105-B63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents","volume":"363","author":"Serruys","year":"2010","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B64","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","article-title":"Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial","volume":"383","author":"von Birgelen","year":"2014","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B65","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1016\/j.jacc.2014.04.013","article-title":"A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial","volume":"63","author":"Park","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B66","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","article-title":"A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial","volume":"59","author":"von Birgelen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B67","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B69","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B70","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.112.104059","article-title":"Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET)","volume":"126","author":"Kimura","year":"2012","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B71","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","article-title":"Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial","volume":"48","author":"Kandzari","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B72","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jacc.2010.03.086","article-title":"Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial","volume":"56","author":"Park","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2016.08.175","article-title":"Differential angioscopic findings of neointimal coverage among first-, second-, and next generation drug-eluting stents","volume":"223","author":"Nakayoshi","year":"2016","journal-title":"Int J Cardiol"},{"key":"2023050214505130900_cvac105-B75","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","article-title":"Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent","volume":"59","author":"Meredith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B76","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B77","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1016\/j.jacc.2018.09.019","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents","volume":"72","author":"Kandzari","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B78","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4244\/EIJ-D-18-00061","article-title":"Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study","volume":"14","author":"Lee","year":"2018","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B79","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.109.877522","article-title":"Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model","volume":"3","author":"Tada","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B80","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1161\/CIRCULATIONAHA.119.040241","article-title":"Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX trial","volume":"141","author":"Lisette O","year":"2020","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.15420\/icr.2016:28:2","article-title":"PCI in patients with diabetes: role of the Cre8 drug-eluting stent","volume":"12","author":"Byrne","year":"2017","journal-title":"Interv Cardiol"},{"key":"2023050214505130900_cvac105-B82","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.118.037707","article-title":"Randomized all-comers evaluation of a permanent polymer zotarolimus-eluting stent versus a polymer-free amphilimus-eluting stent","volume":"139","author":"Rozemeijer","year":"2019","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2017.01.023","article-title":"Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer rEgistry)","volume":"231","author":"Godino","year":"2017","journal-title":"Int J Cardiol"},{"key":"2023050214505130900_cvac105-B84","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17434440.2020.1740587","article-title":"The Cre8 amphilimus-eluting stent for the treatment of coronary artery disease: safety and efficacy profile","volume":"17","author":"Pivato","year":"2020","journal-title":"Expert Rev Med Devices"},{"key":"2023050214505130900_cvac105-B85","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/eurheartj\/ehr384","article-title":"From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?","volume":"33","author":"Serruys","year":"2012","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B86","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","article-title":"A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial","volume":"371","author":"Ormiston","year":"2008","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B87","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.110.970772","article-title":"Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes","volume":"122","author":"Serruys","year":"2010","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B88","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1161\/01.CIR.77.2.361","article-title":"Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months","volume":"77","author":"Serruys","year":"1988","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B89","doi-asserted-by":"publisher","first-page":"280","DOI":"10.5435\/00124635-200109000-00001","article-title":"Bioabsorbable implants in orthopaedics: new developments and clinical applications","volume":"9","author":"Ciccone","year":"2001","journal-title":"J Am Acad Orthop Surg"},{"key":"2023050214505130900_cvac105-B90","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","article-title":"A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods","volume":"373","author":"Serruys","year":"2009","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B91","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","article-title":"Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial","volume":"122","author":"Onuma","year":"2010","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B92","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4244\/EIJ-D-19-00325","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial","volume":"15","author":"Kerkmeijer","year":"2019","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","article-title":"Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial","volume":"37","author":"Sabat\u00e9","year":"2016","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B94","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","article-title":"Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the absorb randomized trials","volume":"137","author":"Ali","year":"2018","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B95","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B96","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4244\/EIJ-D-19-01079","article-title":"Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial","volume":"16","author":"Smits","year":"2020","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B97","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jcin.2014.07.004","article-title":"Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds","volume":"7","author":"Gori","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B98","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4244\/EIJV10I5A103","article-title":"Acute absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?","volume":"10","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2014","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B99","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/eurheartj\/eht168","article-title":"ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases","volume":"34","author":"Ko\u010dka","year":"2013","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B100","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","article-title":"Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings","volume":"66","author":"R\u00e4ber","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B101","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","article-title":"Endothelial cell recovery between comparator polymer-based drug-eluting stents","volume":"52","author":"Joner","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B102","first-page":"C7","article-title":"Pathophysiology of vascular healing and stent mediated arterial injury","volume":"4","author":"Nakazawa","year":"2008","journal-title":"EuroIntervention"},{"key":"2023050214505130900_cvac105-B103","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.jacc.2018.02.051","article-title":"Neoatherosclerosis 5 years after bioresorbable vascular scaffold implantation","volume":"71","author":"Moriyama","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B104","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B105","doi-asserted-by":"publisher","first-page":"e5170","DOI":"10.1136\/bmj.e5170","article-title":"Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials","volume":"345","author":"Bangalore","year":"2012","journal-title":"BMJ"},{"key":"2023050214505130900_cvac105-B106","doi-asserted-by":"publisher","first-page":"e003255","DOI":"10.1161\/CIRCINTERVENTIONS.115.003255","article-title":"Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients","volume":"9","author":"Koskinas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023050214505130900_cvac105-B108","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ahj.2010.11.004","article-title":"Temporal changes in the outcomes of patients with diabetes mellitus undergoing percutaneous coronary intervention in the National Heart, Lung, and Blood Institute dynamic registry","volume":"161","author":"Holper","year":"2011","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B109","doi-asserted-by":"publisher","first-page":"a1331","DOI":"10.1136\/bmj.a1331","article-title":"Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis","volume":"337","author":"Stettler","year":"2008","journal-title":"BMJ"},{"key":"2023050214505130900_cvac105-B110","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/hc3101.093700","article-title":"Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial","volume":"104","author":"Abizaid","year":"2001","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B111","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ahj.2013.04.017","article-title":"Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial","volume":"166","author":"Lima","year":"2013","journal-title":"Am Heart J"},{"key":"2023050214505130900_cvac105-B112","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jacc.2009.09.057","article-title":"Diabetic and nondiabetic patients with left main and\/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents","volume":"55","author":"Banning","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B113","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jacc.2009.10.014","article-title":"Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial","volume":"55","author":"Kapur","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B114","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-11-45","article-title":"Mammalian target of rapamycin signaling in diabetic cardiovascular disease","volume":"11","author":"Chong","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"2023050214505130900_cvac105-B115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2119\/molmed.2010.00023","article-title":"Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes","volume":"16","author":"Ost","year":"2010","journal-title":"Mol Med"},{"key":"2023050214505130900_cvac105-B116","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa1510188","article-title":"Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes","volume":"373","author":"Kaul","year":"2015","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B117","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/eurheartj\/ehab790","article-title":"Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial)","volume":"43","author":"Romaguera","year":"2022","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B118","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B119","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B120","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023050214505130900_cvac105-B121","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B122","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B123","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B124","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(19)31126-2","article-title":"Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial","volume":"394","author":"Rissanen","year":"2019","journal-title":"Lancet"},{"key":"2023050214505130900_cvac105-B125","author":"Byrne"},{"key":"2023050214505130900_cvac105-B126","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2023050214505130900_cvac105-B127","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-Month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B128","doi-asserted-by":"publisher","first-page":"e009565","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B129","doi-asserted-by":"publisher","first-page":"e010144","DOI":"10.1161\/CIRCINTERVENTIONS.120.010144","article-title":"Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent","volume":"14","author":"Kirtane","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"2023050214505130900_cvac105-B130","article-title":"Prospective randomized comparison of the biofreedom biolimus A9 drug-coated stent versus the gazelle bare-metal stent in patients at high bleeding Risk II - LEADERS FREE II","author":"Krukoff","year":"2018","journal-title":"Trans Cardiovasc Ther"},{"key":"2023050214505130900_cvac105-B131","doi-asserted-by":"crossref","first-page":"e023454","DOI":"10.1161\/JAHA.121.023454","article-title":"One-month dual antiplatelet therapy after bioresorbable polymer everolimus-eluting stents in high bleeding risk patients","author":"Pivato","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2023050214505130900_cvac105-B132","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/heartjnl-2020-316745","article-title":"Use of intracoronary imaging to guide optimal percutaneous coronary intervention procedures and outcomes","volume":"107","author":"Mintz","year":"2021","journal-title":"Heart"},{"key":"2023050214505130900_cvac105-B133","doi-asserted-by":"publisher","first-page":"e0130182","DOI":"10.1371\/journal.pone.0130182","article-title":"Optimization of drug delivery by drug-eluting stents","volume":"10","author":"Bozsak","year":"2015","journal-title":"PLoS ONE"},{"key":"2023050214505130900_cvac105-B134","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10237-013-0546-4","article-title":"Modeling the transport of drugs eluted from stents: physical phenomena driving drug distribution in the arterial wall","volume":"13","author":"Bozsak","year":"2014","journal-title":"Biomech Model Mechanobiol"},{"key":"2023050214505130900_cvac105-B135","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1161\/01.CIR.91.6.1676","article-title":"Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance","volume":"91","author":"Colombo","year":"1995","journal-title":"Circulation"},{"key":"2023050214505130900_cvac105-B136","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","author":"Cao","year":"2021","journal-title":"Eur Heart J"},{"key":"2023050214505130900_cvac105-B137","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvac105\/44848852\/cvac105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/3\/631\/50169456\/cvac105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/3\/631\/50169456\/cvac105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:17:41Z","timestamp":1683040661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/119\/3\/631\/6631396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":137,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvac105","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,7,5]]}}}